Transfusion-Transmitted Cytomegalovirus Infection (TT-CMV): A Pilot Study on Safety of Whole-Blood Derivatives

Kelishadi, Mishar; Moradi, Abdolvahab; Samadi, Sobhan; Hashemi, Pezhman; Tabarraei, Alijan

doi:10.5812/scimetr.25718

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…units of RBC or whole blood are transfused in Iran (14). The following strategies have evolved over the recent years for reducing risk of post-transfusion infections: A) careful selection of donors, B) routine screening of blood donors (whole blood) and plasma derivatives for HBV surface antigen and HBV DNA polymerase (Genet Bio, Korea), 1.5 mM MgCl 2 (Genet Bio, Korea) and 2.5 μl 10X PCR buffer (Genet Bio, Korea).…”

Section: Resultsmentioning

confidence: 99%

“…This may have important implications for blood safety. We believe that in countries such as DNA, hepatitis C virus (HCV) antibodies and HCV RNA, HIV-1 and -2 antibodies and HIV-1 RNA, human T-cell lymphotropic virus 1-2 antibodies (in high-incidence areas) and cytomegalovirus antibodies (15), C) viral removal/inactivation technologies, notably dual viral inactivation (solvent/detergent and heat treatment) of blood products and plasma derivatives except whole blood or RBC components (14,16). Due to implementation of the above methods, the risk of transmission of blood-borne viruses, especially HBV, HCV and HIV, through plasma and plasma products has been reduced significantly or eliminated in many areas of the world (16,17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Presence of GB Virus C in Whole-Blood Derivatives: A Pilot Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Red blood cell (RBC) transfusion is necessary for the prevention and treatment of a variety of life-threatening injuries and diseases. However, viral contamination of these products is a great threat to recipients. Screening donors for GB virus C by nucleic acid testing is not routinely implemented worldwide. The aim of the present study was to evaluate prevalence of GBV-C RNA in whole blood/red cell components. Methods: In this cross sectional pilot study, we collected 153 units of packed RBCs from blood banks of two public hospitals in Gorgan (northeast of Iran), between October and November 2014. The samples were screened for the presence of GBV-C RNA in plasma by nested RT-PCR using specific primers targeting highly conserved regions of 5' UTR of GBV-C. Data were analyzed using SPSS software (version 18). Results: Overall, 48 (31.37%) whole blood or red cell components were positive for GBV-C viremia. The GBV-C RNA was detected in 31/88 citrate phosphate dextrose-adenine 1 (CPDA1) RBC, 16/50 washed RBC and 1/13 reduced-leukocyte RBC. However, whole blood CPDA1 was negative for GBV-C viremia. Direct sequencing of PCR products confirmed GBV-C contamination. Conclusions: Transmission of GBV-C infection was observed in blood products. Thus, efforts should be made to develop new strategies for assuring blood transfusion safety.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%